

# ANUPAM RASAYAN INDIA LTD.

ARILSLDSTX20240518012

To,

**BSE** Limited,

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai -400001, India

**SCRIP CODE: 543275** 

To,

**National Stock Exchange of India Limited** 

Date: May 18, 2024

'Exchange Plaza', C-1, Block-G,

Bandra Kurla Complex, Bandra (East),

Mumbai 400051, India

**SYMBOL: ANURAS** 

Dear Sir/ Madam,

# **Subject: Press Release Intimation**

Pursuant to Regulation 30 and other applicable regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed Press Release to be issued by the Company today i.e., Saturday, May 18, 2024, regarding the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2024, approved by the Board of Directors of the Company.

This Press Release will also be hosted on the website of the Company at <a href="https://www.anupamrasayan.com">www.anupamrasayan.com</a>.

We request you to kindly take note the same.

Thanking you,

Yours Faithfully,

For, Anupam Rasayan India Limited

Anand Desai Managing Director DIN: 00038442

Encl.: As above

**Registered Office:** 

Office Nos. 1101 to 1107, 11<sup>th</sup> Floor, Icon Rio, Behind Icon Business Centre, Dumas Road, Surat-395007, Gujarat, India.

Tel. : +91-261-2398991-95
Fax : +91-261-2398996

E-mail : office@anupamrasayan.com
Website : www.anupamrasayan.com

CIN - L24231GJ2003PLC042988

For Immediate dissemination



# **Anupam Rasayan India Limited Reports Q4 & FY24 Results**

Q4FY24 Total Revenue of ₹4,130 Mn; EBITDA Margin at 25%

FY24 Total Revenue of ₹15,053 Mn; EBITDA Margin at 27%

**Surat, May 18, 2024:** Anupam Rasayan India Ltd. (BSE- 543275, NSE- ANURAS, ISIN: INE930P01018), one of India's leading custom synthesis and specialty chemical player, has announced its financial results for the quarter and year ended March 31, 2024.

### Consolidated Financial Highlights for quarter ended March 31, 2024:

- Total revenue for Q4FY24 was at ₹4,130 million as compared to ₹5,042 million in Q4FY23; down 18% YoY.
- EBITDA (incl. other income) was at ₹1,047 million in Q4FY24 as compared to ₹1,416 million in Q4FY23 degrowth of 26% YoY, this would translate into 25% EBITDA margin in this quarter.
- Profit After Tax was at ₹405 million in Q4FY24 as compared to ₹726 million in Q4FY23 degrowth of 44% YoY.

#### Consolidated Financial Highlights for year ended March 31, 2024:

- Total revenue for FY24 was at ₹15,053 million as compared to ₹16,105 million in FY23; down 7% YoY.
- EBITDA (incl. other income) was at ₹4,109 million as compared to ₹4,399 million in FY23 degrowth of 7.0% YoY, this would translate into 27% EBITDA margin.
- Profit After Tax was at ₹1,674 million as compared to ₹2,168 million in FY23 degrowth of 23% YoY.

**Speaking on the performance, Mr Anand Desai, Managing Director, Anupam Rasayan commented,** "Indian chemical industry including spec chem industry has faced significant headwinds during the last year. However, despite the de-growth in the top-line, we have been able to sustain our profitability and maintain margins at 27% levels on a full year consolidated basis. During the year, the Agro chemical industry in particular faced challenges, however our past sustained efforts in expanding our pharma and polymer portfolio have started yielding results leading to pharma contributing over 9% of revenue in FY24, up from 4% last year. We expect pharma and polymer segment each to further increase their revenue share in double digits by next year.

In FY2024, we have focused on expanding our customers, products and end market applications. We have added 17 new molecules, 4 new MNCs including 2 Japanese majors and expanded contribution from polymer and pharma which going forward will lead to balanced product portfolio from end market perspective.

We believe that headwinds in the industry may continue for the next two quarters. However, financial year 2025 will be a year of growth for us with our major focus on polymer and pharmaceutical space."

#### About Anupam Rasayan India Ltd. (ARIL):

Anupam Rasayan India Ltd (ARIL) is one of the leading companies engaged in the custom synthesis (CSM) and manufacturing of specialty chemicals in India. Incorporated in 1984, the speciality chemicals major has two verticals: Life science related Specialty Chemicals comprising products related to Agrochemicals, Personal Care and Pharmaceuticals, Other Specialty Chemicals comprising Polymer Additives. The Company caters to a diverse base of Indian and global customers. It is currently manufacturing products for over 75 domestic and international customers, including 31 multinational companies. The Company operates via its six manufacturing facilities in Gujarat, India, with four facilities located at Sachin, Surat and two located at Jhagadia, Bharuch with an aggregate installed capacity of about 27,000 MT, as of March 31, 2024. ARIL offers multistep synthesis and undertakes complex chemical reactions technologies, for a diverse base of Indian and global customers. The Company is focussed on developing in-house innovative processes for manufacturing products requiring complex chemistries and achieving cost optimization.

#### PRESS RELEASE

For Immediate dissemination



## For further details, please get in touch with:

IR Contact: Ernst & Young LLP Krishna Patel

Email: krishna.patel2@in.ey.com

PR Contact:

Sanchi Yadav

Email: <a href="mailto:sanchi.yadav@adfactorspr.com">sanchi.yadav@adfactorspr.com</a>

Phone: + 91 98336 40764